Datamonitor estimates that there are nearly 86 million Metabolic Syndrome patients in the six major markets. Although the patient pool in need of treatment for Metabolic Syndrome is large, the lack of an approved indication for Metabolic Syndrome, the lack of a consensus definition and the aversion of physicians to pharmacotherapy limit the size of the Metabolic Syndrome market, considerably

• Determination of the prevalence of Metabolic Syndrome and its component conditions
• Evaluation of physician awareness of Metabolic Syndrome and its importance, and of physician perceptions of treatment options for the condition
• Assessment of the potential of existing drug classes and developmental compounds in the treatment of Metabolic Syndrome
• Understanding of the critical issues affecting the Metabolic Syndrome market


Highlights



The lack of a consensus definition for Metabolic Syndrome is complicating the diagnosis and management of patients.





Lifestyle intervention may not be the most rational approach when treating Metabolic Syndrome patients.





The significant patient potential and unmet need characteristic to the Metabolic Syndrome market are counterbalanced by a significant number of challenges.



Reasons to Purchase


• Target physicians more effectively, through an understanding of prescribing behavior and its influences
• Assess the impact that the different definitions of the condition have in the management of Metabolic Syndrome
• Recognize lucrative target populations, in terms of unmet need and patient potential, in order to successfully position developmental products